| Chaudhry, Arvind |
PYRAMID-1, NCT04447118 / 2020-000951-11: Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy |
|
|
| Active, not recruiting | 3 | 151 | Europe, US, RoW | Pyrotinib, Irene, Docetaxel, Docetaxel injection | Jiangsu HengRui Medicine Co., Ltd. | Non-squamous NSCLC, HER2 Exon 20 Mutation | 06/23 | 10/23 | | |
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC |
|
|
| Recruiting | 3 | 200 | US | Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide) | Shanghai Henlius Biotech | Extensive Stage Small Cell Lung Cancer | 10/24 | 12/25 | | |
| Recruiting | 3 | 650 | Europe, Canada, Japan, US, RoW | Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib | Loxo Oncology, Inc., Eli Lilly and Company | Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma | 02/25 | 08/28 | | |
| Recruiting | 1b/2a | 142 | US | TU2218 + Pembrolizumab | TiumBio Co., Ltd., Merck Sharp & Dohme LLC | Solid Tumor | 12/26 | 12/28 | | |
KEYNOTE-F25, NCT05761223: A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and Preliminary Efficacy of FB849 |
|
|
| Recruiting | 1/2 | 151 | US | Phase Ia dose-escalation part of FB849 Monotherapy, FB849, Phase Ib dose-expansion of FB849 monotherapy, Phase IIb dose-escalation part of FB849 in Combination with Pembrolizumab, KEYTRUDA®, Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type A cancer), Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type B cancer), Phase IIb dose-expansion part of FB849 in Combination with Pembrolizumab (Type C cancer) | 1ST Biotherapeutics, Inc., Merck Sharp & Dohme LLC | Advanced Solid Tumor | 06/26 | 10/26 | | |
NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma |
|
|
| Recruiting | 1/2 | 390 | US | ACR-368, prexasertib, Gemcitabine, OncoSignature | Acrivon Therapeutics, GOG Foundation | Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma | 07/26 | 12/27 | | |
ARC-8, NCT04104672: A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies |
|
|
| Recruiting | 1 | 195 | US | AB680, Zimberelimab, AB122, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar | Arcus Biosciences, Inc. | Advanced Pancreatic Cancer | 05/27 | 05/27 | | |
NCT05377996: A Study of XMT-1660 in Participants With Solid Tumors |
|
|
| Recruiting | 1 | 319 | US | XMT-1660 | Mersana Therapeutics | Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma | 12/26 | 05/27 | | |
| Chaudhry, Monika |
ASTRIDE, NCT05468489: To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC |
|
|
| Recruiting | 3 | 200 | US | Serplulimab + chemotherapy (carboplatin-etoposide), Atezolizumab + chemotherapy (carboplatin-etoposide) | Shanghai Henlius Biotech | Extensive Stage Small Cell Lung Cancer | 10/24 | 12/25 | | |
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer |
|
|
| Recruiting | 2/3 | 600 | Europe, US, RoW | SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo | Panbela Therapeutics, Inc. | Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV | 08/26 | 01/27 | | |
NCT05440708: A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma |
|
|
| Recruiting | 1/2 | 166 | US | TTI-101, Pembrolizumab, Keytruda®, Atezolizumab, Tecentriq®, Bevacizumab, Avastin® | Tvardi Therapeutics, Incorporated | Hepatocellular Carcinoma | 03/25 | 03/25 | | |
NCT05548296: A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma |
|
|
| Recruiting | 1/2 | 390 | US | ACR-368, prexasertib, Gemcitabine, OncoSignature | Acrivon Therapeutics, GOG Foundation | Platinum-resistant Ovarian Cancer, Endometrial Adenocarcinoma, Urothelial Carcinoma | 07/26 | 12/27 | | |
| Stahl, Megan |
NCT05865535: A Dose Escalation Study of AV-380 in Metastatic Cancer Patients With Cachexia |
|
|
| Recruiting | 1 | 30 | US | AV-380 | AVEO Pharmaceuticals, Inc. | Cachexia | 07/25 | 09/25 | | |
NCT05050110: Evaluation of Increased Fruits and Vegetables Consumption in Chronic Kidney Disease |
|
|
| Recruiting | N/A | 25 | US | Fruits and Vegetable increase | Nand Wadhwa | Chronic Kidney Diseases | 12/26 | 12/26 | | |
